- ADVERTISEMENT
-
Most Popular
- ADVERTISEMENT
HUM
Cigna Corporation Is Too Late to the Party
Cigna is paying more than its own market cap for ExpressScripts, the largest Pharmacy Benefit Manager.
Humana Inc Earnings Report Didn’t Answer the Right Questions
Humana stock is down just a bit today following its earnings report, extending a recent pullback, because the market can't quite figure out where HUM is going.
5 Stocks Riding High on Stellar Relative Price Strength
Want to try an out-of-the-box approach to earn handsome returns? Tap these stocks with explosive relative price strength. Compare Brokers...
What Remains For Rite Aid Corporation? The Risks of Going It Alone
Rite Aid bulls hope it finds a buyer, while bears see it circling the drain. RAD stock might be fun to trade right now, but watch it closely.
3 Stocks to Watch on Monday: Amazon.com, Inc. (AMZN), CSX Corporation (CSX) and Humana Inc (HUM)
Amazon (AMZN) could face probe over Prime delivery times, CSX's (CSX) CEO died over the weekend and Humana (HUM) is in talks to buy Kindred (KND).
Humana (HUM) a Buy on High-Level Earnings Growth
Humana Inc (NYSE:HUM) is ranked as a Buy using Louis Navellier's Portfolio Grader stock evaluator, which incorporates his investing methodology. This represents no change from the previous week and is the same ranking HUM has had from Portfolio Grader for the last month.
Earnings Growth Make Humana (HUM) a Buy
Humana Inc (NYSE:HUM) is one of 82 companies within the Health Care Providers & Services GICS industry group, which is in turn part of the 782 company GICS Health Care sector. HUM has a market value of $36.9 billion which is in the top decile in its industry group. Portfolio Grader's current ranking for HUM puts it 21 among the 82 companies in this industry group, placing it in the top half; in the top quartile of the sector with a ranking of 182 among the 782 companies in the sector, and number 1,004 in the nearly 5,000 company Portfolio Grader universe.
Humana’s (HUM) Robust Earnings Momentum Make it a Buy
Portfolio Grader currently ranks Humana Inc (NYSE:HUM) a Buy. The approach to investing incorporated in this analytical tool developed by Louis Navellier assesses and ranks nearly 5,000 stocks each week from a fundamental and quantitative perspective. HUM has recently seen its Portfolio Grader rating downgraded over the last month from a Strong Buy to a Buy.
Earnings Growth Keep Humana (HUM) a Buy
Humana Inc (NYSE:HUM) is one of the 781 companies in the GICS Health Care sector, and a constituent of the 82 company Health Care Providers & Services GICS industry group within this sector. HUM's market value is $33.4 billion which places it in the top 10% of its industry group. Portfolio Grader's current ranking for HUM puts it 16 among the 82 companies in this industry group, putting in the top quartile; in the top quartile of the sector with a ranking of 150 among the 781 companies in the sector, and number 974 in the nearly 5,000 company Portfolio Grader universe.
Humana’s (HUM) Quant Score Makes it Buy
Humana Inc (NYSE:HUM) is a $34.9 billion in market value member of the Health Care Providers & Services GICS industry group where Portfolio Grader's current ranking for HUM puts it 17 among the 82 companies in this industry group, giving it a well above-average position. HUM is ranked in the top quartile of the sector with a ranking of 89 among the 782 companies in the sector and number 577 in the 5000 company Portfolio Grader company universe.
Quant Score Metrics Power Humana (HUM) to Strong Buy
Humana Inc (NYSE:HUM) is a $37.1 billion in market value constituent of the Health Care Providers & Services GICS industry group where the stock's Portfolio Grader ranking places it 9 among the 82 companies in this industry group, putting in the top quartile. HUM is ranked in the top decile of the sector with a ranking of 51 among the 785 companies in the sector and number 372 in the 5000 company Portfolio Grader company universe.
Top-End Earnings Momentum Analytics Raise Ranking of Humana (HUM) to Strong Buy
Currently, Humana Inc (NYSE:HUM) has a Strong Buy using Louis Navellier's methods for investing and his Portfolio Grader stock evaluator. The shares have been upgraded from a Buy to a Strong Buy in the last week.
Humana (HUM) a Buy on Strong Earnings Momentum
Portfolio Grader currently ranks Humana Inc (NYSE:HUM) a Buy. Using Louis Navellier's investing methodology, this analytical tool evaluates stocks with fundamental and quantitative metrics. The current Portfolio Grader recommendation on the shares has been in place for the last month.
Humana’s (HUM) Strong Earnings Momentum Makes it a Buy
Humana Inc (NYSE:HUM) is ranked as a Buy using the Portfolio Grader stock evaluator, which incorporates Louis Navellier's investing methodology. This represents no change from the previous week and is the same ranking HUM has had from Portfolio Grader for the last month.
Stock of Humana (HUM) Keeps Strong Buy Rating
Portfolio Grader currently ranks Humana Inc (NYSE:HUM) a Strong Buy. The methodology for fundamental and quantitative metrics used in this analytical tool, developed by Louis Navellier evaluates and ranks nearly 5,000 stocks each week. HUM has maintained this ranking for the last month.
5 Low Leverage Stocks That Can Be Part of Your Portfolio
With the Q3 reporting cycle set to gain steam in the coming weeks, it is reasonable to expect that investors will be more attracted to companies with low levera...
Stock of Humana (HUM) Keeps Strong Buy Rating
Portfolio Grader currently ranks Humana Inc (NYSE:HUM) a Strong Buy. The methodology for fundamental and quantitative metrics used in this analytical tool, developed by Louis Navellier evaluates and ranks nearly 5,000 stocks each week. HUM has maintained this ranking for the last month.
Is This Rite Aid Corporation’s (RAD) Final Earnings Report?
Rite Aid will either merge into Walgreens, find another buyer or disappear. Those buying RAD stock today should expect a sale soon.
